Daily Markets Briefing: STI down 0.23%

Expect some gains today.

The Straits Times Index (STI) ended 8.3 points or 0.23% lower to 3541.91, taking the year-to-date performance to +4.08%.

The top active stocks were DBS, which declined 1.13%, Singtel, which declined 0.55%, OCBC Bank, which declined 0.23%, ThaiBev, which declined 2.13% and UOB, with a 0.46% fall.

The FTSE ST Mid Cap Index gained 0.30%, whilst the FTSE ST Small Cap Index rose 0.23%.

According to OCBC Investment Research, the Dow industrials on Wednesday staged a late rally to end above 26,000 for the first time ever, knocking out another round-number milestone at a history-setting pace for blue chips, with all the main equity indexes finishing at all-time highs.

All eleven S&P 500 industries finished higher, led by Information Technology, which rose 1.58%, and Consumer Staples, which rose 1.17%.

"The strength on Wall Street overnight is likely to provide a modest boost to local bourse today," OCBC said.

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare